Technical Analysis for OSL - Oncosil Medical Ltd
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 0.004 | -20.00% | -0.001 |
Earnings due: May 15
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| MACD Bearish Signal Line Cross | Bearish | 0.00% | |
| New 52 Week Closing Low | Bearish | 0.00% | |
| Reversal New Lows Setup | Bearish Swing Setup | 0.00% | |
| New 52 Week Low | Weakness | 0.00% | |
| Stochastic Reached Oversold | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Fell Below 20 DMA | Bearish | -20.00% |
| Alert | Time |
|---|---|
| Lower Bollinger Band Support | about 22 hours ago |
| Reversed from Down | about 22 hours ago |
| Down 10% | about 24 hours ago |
| Down 1 ATR | about 24 hours ago |
| Fell Below Previous Day's Low | about 24 hours ago |
Free Daily (Stock) Chart Reading
Oncosil Medical Ltd Description
OncoSil Medical Limited is a late-stage medical device company, which is focused on localized treatments for patients with pancreatic and liver cancer. The Company is engaged in the development of its lead product candidate, the OncoSil localized radiation therapy, for the treatment of pancreatic cancer. The Company's lead product, OncoSil, is a brachytherapy device that emits beta radiation and is implanted directly inside the cancerous tumor. OncoSil is a silicon and phosphorus (p32) beta emitter, able to be implanted intra-tumorally via endoscopic ultrasonography in localized solid tumors of patients with pancreatic cancer. The Company focuses on an application for Conformite Europeene (CE) Mark to enable commercial sales of OncoSil in the European Union and an application for an Investigational Device Exemption (IDE) from the United States Food and Drug Administration (FDA) to enable commencement of the United States pivotal clinical study, known as OncoPac-1.
Classification
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Health Medicine Food Cement Cancer Medical Device Implant Therapy Medical Physics Tumor Radiation Tumors European Union Radiation Therapy Solid Tumors Pancreatic Cancer Phosphorus Pivot Radioactivity
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 0.015 |
| 52 Week Low | 0.004 |
| Average Volume | 3,528,392 |
| 200-Day Moving Average | 0.009 |
| 50-Day Moving Average | 0.007 |
| 20-Day Moving Average | 0.006 |
| 10-Day Moving Average | 0.006 |
| Average True Range | 0.001 |
| RSI (14) | 47.37 |
| ADX | 19.46 |
| +DI | 18.750 |
| -DI | 34.821 |
| Chandelier Exit (Long, 3 ATRs) | 0.005 |
| Chandelier Exit (Short, 3 ATRs) | 0.006 |
| Upper Bollinger Bands | 0.008 |
| Lower Bollinger Band | 0.004 |
| Percent B (%b) | -0.03 |
| BandWidth | 58.621 |
| MACD Line | 0.000 |
| MACD Signal Line | 0.000 |
| MACD Histogram | 0.0 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.006 | ||||
| Resistance 3 (R3) | 0.006 | 0.005 | 0.005 | ||
| Resistance 2 (R2) | 0.005 | 0.005 | 0.005 | 0.005 | |
| Resistance 1 (R1) | 0.005 | 0.005 | 0.005 | 0.005 | 0.005 |
| Pivot Point | 0.004 | 0.004 | 0.004 | 0.004 | 0.004 |
| Support 1 (S1) | 0.004 | 0.004 | 0.004 | 0.004 | 0.003 |
| Support 2 (S2) | 0.003 | 0.004 | 0.003 | 0.003 | |
| Support 3 (S3) | 0.003 | 0.003 | 0.003 | ||
| Support 4 (S4) | 0.003 |
